Evaluation of surgical outcomes and prognostic factors of second primary lung cancer based on a systematic review and meta-analysis
Jie Zhao(Kunming Medical University), Lianhua Ye(Kunming Medical University), Wei Wang(Central South University), Yunchao Huang(North China University of Water Resources and Electric Power), Yantao Yang(Kunming Medical University), Guangqiang Zhao(Kunming Medical University), Zhenghai Shen(Kunming Medical University), Zhou Chen(Kunming Medical University)
Cited by 11
Related Papers
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China
|SSRN Electronic Journal|2020|963
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508